论坛 › 上海 › 2024年值得关注的5种癌症疫苗！

tw4ld6 发表于 2024-5-21 13:26:19

2024年值得关注的5种癌症疫苗！

    <h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;"><strong style="color: blue;"><span style="color: black;">▎药明康德内容团队编辑</span></strong></strong></h1>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">癌症疫苗是一个<span style="color: black;">快速</span>发展的<span style="color: black;">行业</span>，<span style="color: black;">针对</span>改善癌症治疗<span style="color: black;">拥有</span>重大<span style="color: black;">道理</span>。这些疫苗与传统的预防性疫苗不同，<strong style="color: blue;">治疗性癌症疫苗专门用于强化<span style="color: black;">病人</span>的免疫系统，使其能够识别并攻击癌细胞。</strong>得益于个体化医疗的前沿<span style="color: black;">发展</span>，<strong style="color: blue;">如今<span style="color: black;">咱们</span>能够<span style="color: black;">经过</span>对<span style="color: black;">病人</span>的基因组进行测序来识别其独特的癌症特征，这些信息使<span style="color: black;">咱们</span>有能力<span style="color: black;">研发</span>出针对特定新抗原的癌症疫苗</strong>。本文将介绍五种<span style="color: black;">日前</span>正<span style="color: black;">处在</span>中后期<span style="color: black;">研发</span><span style="color: black;">周期</span>的癌症疫苗，并概述它们在临床<span style="color: black;">实验</span>中展示的积极效果。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">药品</span>名<span style="color: black;">叫作</span>：V940/mRNA-4157</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">开发</span><span style="color: black;">机构</span>：Moderna和默沙东（MSD）</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">研发</span><span style="color: black;">周期</span>：3期临床</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">适应症：经手术切除高<span style="color: black;">危害</span>黑色素瘤（IIB-IV期）</strong></span></p><img src="https://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gPhhAib13LrCp9KdS66X8EdgswoJozwIVick6fLkAY07hQmrSoTibL6MZz6KqaykDqSsbabS5ib88usPA/640?wx_fmt=jpeg&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">mRNA-4157癌症疫苗<span style="color: black;">包括</span>编码最多34种新抗原的单一合成mRNA分子，该疫苗是<span style="color: black;">按照</span>每位<span style="color: black;">病人</span>肿瘤独特的DNA序列突变特征<span style="color: black;">经过</span>算法设计而成</span></strong><span style="color: black;">。当将此癌症疫苗注射入<span style="color: black;">身体</span>时，这些RNA所携带的新抗原序列会被翻译成蛋白质，并<span style="color: black;">经过</span><span style="color: black;">身体</span>的抗原呈递，刺激产生T细胞抗肿瘤反应。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">在今年美国临床肿瘤学会（ASCO）年会<span style="color: black;">其中</span>，两家<span style="color: black;">机构</span><span style="color: black;">颁布</span>了mRNA-4157与PD-1<span style="color: black;">控制</span>剂Keytruda组合，在157位经手术切除高<span style="color: black;">危害</span>黑色素瘤（III/IV期）<span style="color: black;">病人</span>中的疗效与安全性。在总意向治疗（ITT）人群中，<strong style="color: blue;">mRNA-4157与Keytruda联合的辅助治疗在次要终点<span style="color: black;">没</span>远处转移<span style="color: black;">存活</span>期（DMFS）上<span style="color: black;">表示</span>出统计学<span style="color: black;">明显</span>和临床有<span style="color: black;">道理</span>的改善，与单独<span style="color: black;">运用</span>Keytruda相比，降低肿瘤产生远处转移或死亡的<span style="color: black;">危害</span>达65%</strong>（HR=0.347，95% CI：0.145-0.828；单侧P值=0.0063）。<span style="color: black;">按照</span>临床2b期<span style="color: black;">实验</span>KEYNOTE-942的数据，美国FDA和欧洲<span style="color: black;">药物</span>管理局（EMA）分别授予mRNA-4157与Keytruda组合突破性疗法认定和PRIME资格，<span style="color: black;">做为</span>辅助疗法用以治疗完全切除后的高<span style="color: black;">危害</span>黑色素瘤<span style="color: black;">病人</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">今年7月，默沙东和Moderna<span style="color: black;">机构</span>宣布</span><a style="color: black;"><span style="color: black;"><span style="color: black;">起步</span></span></a><span style="color: black;">V940-001<span style="color: black;">重要</span>性3期临床<span style="color: black;">实验</span>，以<span style="color: black;">评定</span>mRNA-4157联合Keytruda<span style="color: black;">做为</span>经手术切除高<span style="color: black;">危害</span>黑色素瘤（IIB-IV期）<span style="color: black;">病人</span>辅助疗法的疗效与安全性。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">药品</span>名<span style="color: black;">叫作</span>：autogene cevumeran（RG6180）</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">研发<span style="color: black;">机构</span>：BioNTech，基因泰克（Genentech）</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">研发</span><span style="color: black;">周期</span>：2期临床</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">适应症：胰腺导管腺癌（PDAC）</strong></span></p><img src="https://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gMG3uiam2kt6OP3NQ05PyBia9JSokRoTicacnsM8JGLFuUCXZKQqkTiawNYwKsf1icH0slZ7Jp8ibmcgknQ/640?wx_fmt=jpeg&amp;from=appmsg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">Autogene cevumeran<span style="color: black;">是由于</span>BioNTech和罗氏（Roche）旗下的基因泰克联合<span style="color: black;">研发</span>的一款个体化新抗原疫苗。<strong style="color: blue;">该<span style="color: black;">药品</span>是基于BioNTech的iNeST癌症疫苗技术平台生成的，<span style="color: black;">能够</span>编码数十种新抗原，</strong><strong style="color: blue;">旨在激发人体针对肿瘤细胞产生更为全面的免疫反应，防止肿瘤细胞逃避免疫系统的攻击。</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">今年5月，《自然》杂志<span style="color: black;">发布</span>了该疫苗与抗PD-L1抗体atezolizumab和化疗联用治疗胰腺癌的</span><a style="color: black;"><span style="color: black;"><span style="color: black;">初期</span>临床结果</span></a><span style="color: black;">。<span style="color: black;">实验</span>结果<span style="color: black;">表示</span>，<strong style="color: blue;">这种治疗组合<span style="color: black;">明显</span>推迟接受手术切除的胰腺癌<span style="color: black;">病人</span>的复发时间，凸显了mRNA癌症疫苗的抗癌<span style="color: black;">潜能</span></strong>。<span style="color: black;">另外</span>，该疫苗在<span style="color: black;">实验</span>过程中表现出良好的安全性，并成功诱导出了靶向胰腺癌癌症新抗原的T细胞活性。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">日前</span>，autogene cevumeran正<span style="color: black;">处在</span>2期临床<span style="color: black;">科研</span><span style="color: black;">周期</span>。除了针对PDAC，另有针对结直肠癌和黑色素瘤的2期临床<span style="color: black;">实验</span>正在进行中。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">药品</span>名<span style="color: black;">叫作</span>：TG4050</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">开发</span><span style="color: black;">机构</span>：Transgene，NEC</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">研发</span><span style="color: black;">周期</span>：1期临床（2期临床<span style="color: black;">实验</span>即将<span style="color: black;">起步</span>）</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">适应症：卵巢癌，HPV阴性头颈癌</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gMFa3Hdlj9zEYp176scqqknX1sFQiaDKPtqMhtFc2GV6f8Kxkm000KukFTIsVwA1FNdwQMnvNqgL7g/640?wx_fmt=jpeg&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">TG4050是一款由Transgene和NEC<span style="color: black;">机构</span>联合<span style="color: black;">研发</span>的一款基于MVA病毒载体的治疗性疫苗，该载体已被证明<span style="color: black;">拥有</span>生物活性并<span style="color: black;">拥有</span><span style="color: black;">诱发</span>针对肿瘤抗原的免疫应答的能力<strong style="color: blue;">。TG4050表达利用NEC<span style="color: black;">机构</span>的人工智能（AI）算法<span style="color: black;">选取</span>的肿瘤新抗原，NEC<span style="color: black;">机构</span>的AI新抗原预测系统<span style="color: black;">能够</span>识别和<span style="color: black;">选取</span><span style="color: black;">病人</span>的特异性突变，TG4050表达的30多种肿瘤新抗原均由NEC的AI系统<span style="color: black;">选取</span>。</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">今年6月，Transgene和NEC<span style="color: black;">机构</span>在2023年ASCO年会上展示了TG4050治疗HPV阴性头颈癌<span style="color: black;">病人</span>的1期<span style="color: black;">实验</span>的新数据。数据<span style="color: black;">显示</span>，<strong style="color: blue;">所有可<span style="color: black;">评定</span>的<span style="color: black;">病人</span>在接受TG4050治疗后都对多种癌症新抗原产生了特异性免疫应答，<span style="color: black;">包括</span><span style="color: black;">哪些</span>在基线时全身免疫状态和肿瘤微环境<span style="color: black;">有害</span>免疫反应产生的<span style="color: black;">病人</span>（例如存在非功能性免疫细胞或PD-L1表达量低或阴性）</strong>。<span style="color: black;">拥有</span>这些挑战性免疫特征的<span style="color: black;">病人</span><span style="color: black;">一般</span>对<span style="color: black;">包含</span>免疫<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂在内的疗法应答有限。两家<span style="color: black;">机构</span>还报告了两个病例<span style="color: black;">科研</span>。在这些接受TG4050治疗后保持缓解状态的<span style="color: black;">病人</span>中，<span style="color: black;">经过</span>四聚体染色（tetramer staining）<span style="color: black;">评定</span>了其对靶标抗原所产生的免疫活性T细胞应答。<strong style="color: blue;">结果证实这些<span style="color: black;">病人</span>的免疫活性T细胞频率大幅<span style="color: black;">增多</span></strong>。这些T细胞被确认为效应细胞毒性T细胞，这是一种<span style="color: black;">拥有</span>潜在抗肿瘤活性的细胞群。<strong style="color: blue;">这些数据进一步证明，TG4050能够诱导抗肿瘤细胞免疫应答。</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">日前</span>，该疫苗正在进行治疗卵巢癌和HPV阴性头颈癌的1期临床<span style="color: black;">实验</span>。<span style="color: black;">同期</span>，为了进一步探索TG4050在头颈癌辅助治疗中的<span style="color: black;">潜能</span>，Transgene和NEC<span style="color: black;">机构</span>正筹备开展一项2期临床<span style="color: black;">实验</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">药品</span>名<span style="color: black;">叫作</span>：Tedopi</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">开发</span><span style="color: black;">机构</span>：OSE Immunotherapeutics</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">研发</span><span style="color: black;">周期</span>：2期临床</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">适应症：晚期非小细胞肺癌（NSCLC），PDAC，复发性卵巢癌</strong></span></p><img src="https://mmbiz.qpic.cn/mmbiz_png/FcLK21Ir4gN5ThIpHGcSicXAGU8gLIpzmvVkS2qMaIVsiaIfqDavzsWEy7JMkxoXBceWYC4cwF0uz4yCADzRoCpg/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">Tedopi是OSE Immunotherapeutics<span style="color: black;">机构</span><span style="color: black;">研发</span>的一种癌症疫苗，它的设计非常有特点：<strong style="color: blue;">从5个肿瘤<span style="color: black;">关联</span>抗原中筛选出10个最佳新抗原表位（neo-epitope），再进行组合，刺激T淋巴细胞识别和攻击癌细胞</strong>。<span style="color: black;">初期</span><span style="color: black;">科研</span>证明，Tedopi可激发细胞毒性T细胞对癌细胞的特异性反应和<span style="color: black;">关联</span>的辅助型T细胞反应。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">按照</span>今年9月<span style="color: black;">发布</span>在Annals of Oncology杂志上的<span style="color: black;">科研</span>结果，<span style="color: black;">针对</span><span style="color: black;">哪些</span>在连续接受化疗和免疫<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂治疗<span style="color: black;">最少</span>12周后仍<span style="color: black;">显现</span>病情<span style="color: black;">发展</span>的HLA-A2阳性晚期或转移性NSCLC<span style="color: black;">病人</span>，<strong style="color: blue;">Tedopi<span style="color: black;">做为</span>单药疗法与化疗相比，不仅<span style="color: black;">能够</span><span style="color: black;">加强</span>总<span style="color: black;">存活</span>率，<span style="color: black;">况且</span><span style="color: black;">拥有</span>更好的安全性和生活质量。</strong>这些结果为<span style="color: black;">哪些</span><span style="color: black;">已然</span>用尽常规治疗<span style="color: black;">办法</span>、<span style="color: black;">无</span>太多其他<span style="color: black;">选取</span>的<span style="color: black;">病人</span>带来了<span style="color: black;">期盼</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">日前</span>，Tedopi正在进行2期临床<span style="color: black;">实验</span>，旨在治疗PDAC和复发性卵巢癌<span style="color: black;">病人</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">药品</span>名<span style="color: black;">叫作</span>：VB10.16</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">开发</span><span style="color: black;">机构</span>：Nykode Therapeutics</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">研发</span><span style="color: black;">周期</span>：2期临床</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">适应症：HPV16阳性宫颈癌，HPV16阳性头颈部鳞状细胞癌（HNSCC）</strong></span></p><img src="https://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gPribujPRDmddl2YvqzHpY9GUKNoL9rgObqlqicn0NcLr7iaR5odVOhtZecmqPmVFu6c9wsIGibJZH29Q/640?wx_fmt=jpeg&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">VB10.16是Nykode Therapeutics<span style="color: black;">开发</span>的一款表达HPV16抗原的DNA质粒疫苗，它利用了Nykode<span style="color: black;">机构</span>专有的模块化Vaccibody技术平台，<strong style="color: blue;"><span style="color: black;">经过</span>将抗原靶向递送到抗原呈递细胞中（APC），诱导快速、强大和持久的特异性免疫反应。</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">该疫苗联合PD-L1抑制剂atezolizumab，在治疗HPV16阳性晚期宫颈癌<span style="color: black;">病人</span>的2期临床<span style="color: black;">实验</span>中取得了积极的疗效。中期结果<span style="color: black;">表示</span>，<strong style="color: blue;">中位随访时间为6个月时，在39名<span style="color: black;">病人</span>中，客观缓解率（ORR）为21%（<span style="color: black;">包含</span>2名完全缓解和6名部分缓解的<span style="color: black;">病人</span>），<span style="color: black;">疾患</span><span style="color: black;">掌控</span>率（DCR）达到了64%</strong>。该<span style="color: black;">实验</span>招募的对象是接受<span style="color: black;">太多</span>次前期治疗的<span style="color: black;">病人</span>群体，其中超过三分之二的<span style="color: black;">病人</span><span style="color: black;">已然</span>接受了<span style="color: black;">最少</span>两种全身治疗，这些结果<span style="color: black;">没</span>疑为这些治疗<span style="color: black;">选取</span>有限的难治性<span style="color: black;">病人</span>群体带来了福音。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">除了针对HPV16阳性晚期宫颈癌的2期临床<span style="color: black;">实验</span>，VB10.16还在针对HPV16阳性HNSCC的1期临床<span style="color: black;">实验</span>中进行测试。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">癌症疫苗<span style="color: black;">行业</span>正在经历迅猛发展，文中所列举的这五种疫苗仅仅是<span style="color: black;">全部</span><span style="color: black;">行业</span>的冰山一角。随着<span style="color: black;">科研</span>人员<span style="color: black;">持续</span>探索和<span style="color: black;">研发</span>利用免疫系统对抗癌症的新<span style="color: black;">办法</span>，<span style="color: black;">咱们</span>期待在<span style="color: black;">将来</span>几年里将会<span style="color: black;">显现</span><span style="color: black;">更加多</span>前景广阔的候选<span style="color: black;">药品</span>。尽管<span style="color: black;">将来</span>的路还很长，但<span style="color: black;">迄今</span>取得的<span style="color: black;">明显</span><span style="color: black;">发展</span>让<span style="color: black;">咱们</span>对<span style="color: black;">将来</span>感到<span style="color: black;">阳光</span>，<span style="color: black;">亦</span>让全世界数百万癌症<span style="color: black;">病人</span>看到了<span style="color: black;">期盼</span>。</span></p><img src="https://mmbiz.qpic.cn/mmbiz_svg/7N2JRaWooRDKGCJV2d31jN4vr7hb0qqlhiaJ3QuqiaxjvCFuBjic1LVZErPvYGDbicbSZm937N5K260X3icfq5icADKsiaYQmtHUx3W/640?&amp;wx_fmt=svg&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">大众</span>都在看</strong></p><img src="https://mmbiz.qpic.cn/mmbiz_svg/XCopLcwfzed1hWjqibq9qdpJd5ar8StfVocc6foo1hGQB7h0WW3lQRN2pZSmUBHgTniawjibicKnb9JpZsopCDfbmGtvKxGNw99T/640?&amp;wx_fmt=svg&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gMVSQQEnEPVmaGAkicp4k0fVGfaFlRIIvib7hVlWfDgDcklxUgmBGRedb9WtpRICOrC3hgHiblEPqh8Q/640?wx_fmt=jpeg&amp;from=appmsg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gMVSQQEnEPVmaGAkicp4k0fVD8WtsKiaibYGWP52VKdh916qSdAj6T064NZSpZnmMvq0QWkNNMkFS9fA/640?wx_fmt=jpeg&amp;from=appmsg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gMVSQQEnEPVmaGAkicp4k0fV2gKvLWhicVuF5Zghr0Xl1Qtlk7lyCnyYia5NqXU3XLQqQyI5dxXhemnQ/640?wx_fmt=jpeg&amp;from=appmsg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_png/iad7f8nGcGovLXpOJFNeib3S1oDhOSKWGIksVAMbbmwwHfvCEyREyZIRwJbEaqhaqodEtmflrgBQ6tiaPzXnkibRVA/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span></a></p><span style="color: black;"><span style="color: black;">药明康德为<span style="color: black;">全世界</span>生物医药行业<span style="color: black;">供给</span>一体化、端到端的新药<span style="color: black;">开发</span>和生产服务，服务范围涵盖化学药<span style="color: black;">开发</span>和生产、生物学<span style="color: black;">科研</span>、临床前测试和临床<span style="color: black;">实验</span><span style="color: black;">开发</span>、细胞及基因疗法<span style="color: black;">开发</span>、测试和生产等<span style="color: black;">行业</span>。</span><span style="color: black;">如您有<span style="color: black;">关联</span>业务需求，欢迎点击下方<span style="color: black;">照片</span>填写<span style="color: black;">详细</span>信息。</span></span><img src="https://mmbiz.qpic.cn/mmbiz_png/FcLK21Ir4gMFgssaEa1M6OvbN9QQSdTncQ402Uxs2XKYpsbsiafBXnyFVdrWvkoQ0OHM01T6XbLS9x2eZOGNc3w/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;">
    <h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;"><span style="color: black;">▲</span></strong><strong style="color: blue;">如您有任何业务需求，请长按扫描上方二维码，或点击文末“阅读原文/Read more”，<span style="color: black;">就可</span><span style="color: black;">拜访</span>业务对接平台，填写业务需求信息</strong></h1>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_gif/FcLK21Ir4gPlQfkXJBbBkTkBPyhC6liaY5JWLCul2eywweQlq9wKV6GuhJ2FaIiaIic7YshwURh8aD9az4TpmBPuA/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
    <h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">▲</span>欲<span style="color: black;">认识</span><span style="color: black;">更加多</span>前沿技术在生物医药产业中的应用，请长按扫描上方二维码，<span style="color: black;">就可</span><span style="color: black;">拜访</span>“药明直播间”，观看<span style="color: black;">关联</span><span style="color: black;">专题</span>的直播讨论与精彩回放</span></strong></h1><span style="color: black;">参考资料：</span><span style="color: black;"> 5 Cancer Vaccines to Watch in 2024，Retrieved November 22, 2023, from https://www.biospace.com/article/5-cancer-vaccines-to-watch-in-2024/</span><span style="color: black;"> 940-001 IS THE FIRST PHASE 3 STUDY OF A PLANNED COMPREHENSIVE CLINICAL DEVELOPMENT PROGRAM BEING INITIATED FOLLOWING THE POSITIVE PRIMARY ANALYSIS OF THE PHASE 2B KEYNOTE-942/MRNA-4157-P201 TRIAL REPORTED AT AACR AND ASCO EARLIER THIS YEAR. Retrieved November 22, 2023, from https://investors.modernatx.com/news/news-details/2023/Merck-and-Moderna-Initiate-Phase-3-Study-Evaluating-V940-mRNA-4157-in-Combination-with-KEYTRUDA-pembrolizumab-for-Adjuvant-Treatment-of-Patients-with-Resected-High-Risk-Stage-IIB-IV-Melanoma/default.aspx</span><span style="color: black;"> Rojas et al., (2023). Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature, https://doi.org/10.1038/s41586-023-06063-y</span><span style="color: black;"> Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023. Retrieved November 22, 2023, from https://www.transgene.fr/wp-content/uploads/20230606_Transgene_NEC_ASCO_TG4050_EN.pdf</span><span style="color: black;"> OSE Immunotherapeutics To Present Positive Results of Tedopi® Phase 3 Clinical Trial in Non-Small Cell Lung Cancer Patients in Secondary Resistance to Immune Checkpoint Inhibitors. Retrieved November 22, 2023, from https://www.businesswire.com/news/home/20210919005032/en/OSE-Immunotherapeutics-To-Present-Positive-Results-of-Tedopi%C2%AE-Phase-3-Clinical-Trial-in-Non-Small-Cell-Lung-Cancer-Patients-in-Secondary-Resistance-to-Immune-Checkpoint-Inhibitors</span><span style="color: black;">OSE Immunotherapeutics Announces: Positive Phase 3 Data from its Cancer Vaccine in Lung Cancer Patients with Resistance to Previous Immunotherapy Published in Annals of Oncology，Retrieved November 22, 2023, from https://www.biospace.com/article/releases/ose-immunotherapeutics-announces-positive-phase-3-data-from-its-cancer-vaccine-in-lung-cancer-patients-with-resistance-to-previous-immunotherapy-published-in-annals-of-oncology/</span><span style="color: black;"> Nykode Therapeutics announces positive interim results from its Phase 2 trial with VB10.16 in combination with immune checkpoint inhibitor atezolizumab in advanced cervical cancer. Retrieved November 22, 2023, from https://www.globenewswire.com/news-release/2022/05/09/2438179/0/en/Nykode-Therapeutics-announces-positive-interim-results-from-its-Phase-2-trial-with-VB10-16-in-combination-with-immune-checkpoint-inhibitor-atezolizumab-in-advanced-cervical-cancer.html</span><span style="color: black;">免责声明：药明康德内容团队专注介绍<span style="color: black;">全世界</span>生物医药健康<span style="color: black;">科研</span><span style="color: black;">发展</span>。本文仅作信息交流之目的，文中观点不<span style="color: black;">表率</span>药明康德立场，<span style="color: black;">也</span>不<span style="color: black;">表率</span>药明康德支持或反对文中观点。本文<span style="color: black;">亦</span>不是治疗<span style="color: black;">方法</span><span style="color: black;">举荐</span>。如需<span style="color: black;">得到</span>治疗<span style="color: black;">方法</span><span style="color: black;">指点</span>，请前往正规医院就诊。</span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">版权说明：本文来自药明康德内容团队，欢迎个人转发至<span style="color: black;">伴侣</span>圈，谢绝<span style="color: black;">媒介</span>或<span style="color: black;">公司</span>未经授权以任何形式转载至其他平台。转载授权请在「药明康德」<span style="color: black;">微X</span>公众号回复“转载”，获取转载须知。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_gif/FcLK21Ir4gMQibRNf9bAu7ia8icFMqc0eMVYURp6S5H6iatzQCLKl8IhWglTy1F5U4w8BicFDiaB3cicjc9Y6QkMCp00Q/640?wx_fmt=gif&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1" style="width: 50%; margin-bottom: 20px;"></p><img src="https://mmbiz.qpic.cn/mmbiz_gif/EIicaxb3hLFVnNzPUokQuwswWsanJWXTUZhjvvN3TI1QEwQUvwkhGn1muiaM37vs5iaQST1zRzYB7CQ5R6kILjvmg/640?wx_fmt=gif&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">分享</strong></span>，<strong style="color: blue;"><span style="color: black;">点</span></strong><strong style="color: blue;"><span style="color: black;">赞</span></strong>，<strong style="color: blue;"><span style="color: black;">在看</span></strong>，聚焦<span style="color: black;">全世界</span>生物医药健康创新</p>

听听海 发表于 2024-8-22 03:57:34

你的言辞如同繁星闪烁，点亮了我心中的夜空。

情迷布拉格 发表于 2024-8-22 13:27:32

说得好啊！我在外链论坛打滚这么多年，所谓阅人无数，就算没有见过猪走路，也总明白猪肉是啥味道的。

听听海 发表于 2024-9-5 21:56:47

i免费外链发布平台 http://www.fok120.com/

m5k1umn 发表于 2024-10-26 18:01:05

我们有着相似的经历，你的感受我深有体会。

1fy07h 发表于 2024-10-28 06:20:29

认真阅读了楼主的帖子，非常有益。

查看完整版本: 2024年值得关注的5种癌症疫苗！